BG105197A - Полиморфна форма на лекарствено средство - Google Patents

Полиморфна форма на лекарствено средство

Info

Publication number
BG105197A
BG105197A BG10519701A BG10519701A BG105197A BG 105197 A BG105197 A BG 105197A BG 10519701 A BG10519701 A BG 10519701A BG 10519701 A BG10519701 A BG 10519701A BG 105197 A BG105197 A BG 105197A
Authority
BG
Bulgaria
Prior art keywords
medicament
polymorph form
ritonavir
figures
preparation
Prior art date
Application number
BG10519701A
Other languages
English (en)
Other versions
BG65150B1 (bg
Inventor
John Bauer
- GERHARDT Azita SALEKI
Bikshandarkoil NARAYANAN
Sanjay Chemburkar
Ketan Patel
Harry Spiwek
Philip Bauer
Kimberly Allen
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG105197(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG105197A publication Critical patent/BG105197A/bg
Publication of BG65150B1 publication Critical patent/BG65150B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретението се отнася до нова полиморфна форма на ритонавир, наречена форма II, както и до методиза получаването и приложението й.
BG105197A 1998-07-20 2001-01-30 Кристална полиморфна форма на ритонавир и метод за получаването й BG65150B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04

Publications (2)

Publication Number Publication Date
BG105197A true BG105197A (bg) 2001-10-31
BG65150B1 BG65150B1 (bg) 2007-04-30

Family

ID=26817251

Family Applications (4)

Application Number Title Priority Date Filing Date
BG105197A BG65150B1 (bg) 1998-07-20 2001-01-30 Кристална полиморфна форма на ритонавир и метод за получаването й
BG109682A BG65963B1 (bg) 1998-07-20 2006-09-20 Аморфен ритонавир и метод за неговото получаване
BG110080A BG110080A (bg) 1998-07-20 2006-09-20 Ритонавир, метод за неговото получаване и използването му
BG10110080A BG66140B1 (bg) 1998-07-20 2008-03-12 Фармацевтичен състав, съдържащ кристална форма іі ритонавир и метод за неговото получаване

Family Applications After (3)

Application Number Title Priority Date Filing Date
BG109682A BG65963B1 (bg) 1998-07-20 2006-09-20 Аморфен ритонавир и метод за неговото получаване
BG110080A BG110080A (bg) 1998-07-20 2006-09-20 Ритонавир, метод за неговото получаване и използването му
BG10110080A BG66140B1 (bg) 1998-07-20 2008-03-12 Фармацевтичен състав, съдържащ кристална форма іі ритонавир и метод за неговото получаване

Country Status (30)

Country Link
EP (4) EP1418174B1 (bg)
JP (4) JP4815050B2 (bg)
KR (3) KR100740796B1 (bg)
CN (5) CN101259128A (bg)
AR (5) AR019431A1 (bg)
AT (3) ATE425974T1 (bg)
AU (1) AU768207B2 (bg)
BG (4) BG65150B1 (bg)
BR (1) BR9912010A (bg)
CA (3) CA2674800A1 (bg)
CO (1) CO5090830A1 (bg)
CY (2) CY1111600T1 (bg)
CZ (2) CZ307116B6 (bg)
DE (2) DE69915628T2 (bg)
DK (3) DK2017269T3 (bg)
ES (3) ES2372990T3 (bg)
HK (2) HK1037918A1 (bg)
HU (3) HU229999B1 (bg)
ID (1) ID27996A (bg)
IL (4) IL140492A0 (bg)
MY (2) MY121765A (bg)
NO (2) NO318385B1 (bg)
NZ (2) NZ522690A (bg)
PL (2) PL213978B1 (bg)
PT (3) PT1097148E (bg)
SI (3) SI1097148T1 (bg)
SK (3) SK287381B6 (bg)
TR (1) TR200100171T2 (bg)
TW (3) TWI227713B (bg)
WO (1) WO2000004016A2 (bg)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
CA2371109C (en) * 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations
JP2005508294A (ja) * 2001-05-25 2005-03-31 アボット・ラボラトリーズ リトナビルおよび／またはロピナビルを含む軟弾性カプセル
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
EP1891027A1 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited Processes for the preparation of stable polymorphic form i of ritonavir
WO2008041176A2 (en) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
EP2822553B1 (en) 2012-03-07 2016-05-18 ratiopharm GmbH Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
CA2866206A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
EP3038607A2 (en) 2013-08-29 2016-07-06 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DK1302468T3 (da) * 1992-12-29 2009-03-02 Abbott Lab Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
CA2371109C (en) * 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations

Also Published As

Publication number Publication date
AU768207B2 (en) 2003-12-04
SK286388B6 (sk) 2008-09-05
ID27996A (id) 2001-05-03
TWI227713B (en) 2005-02-11
KR100740796B1 (ko) 2007-07-20
DK2017269T3 (da) 2012-03-05
EP1097148A2 (en) 2001-05-09
HU229999B1 (en) 2015-04-28
BG110080A (bg) 2008-11-28
AR059764A2 (es) 2008-04-30
HU230150B1 (hu) 2015-09-28
CN102153524A (zh) 2011-08-17
AR044029A2 (es) 2005-08-24
EP2017269A9 (en) 2009-10-14
PT2017269E (pt) 2011-12-20
MY121765A (en) 2006-02-28
WO2000004016A3 (en) 2000-03-30
EP2017269A3 (en) 2009-06-10
DK1097148T3 (da) 2004-04-26
BG66140B1 (bg) 2011-07-29
CA2337846A1 (en) 2000-01-27
ES2322759T3 (es) 2009-06-26
CY1111600T1 (el) 2015-10-07
HU0800266D0 (en) 2008-06-30
IL187181A (en) 2009-09-01
JP2010270135A (ja) 2010-12-02
NO20010298D0 (no) 2001-01-18
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
CA2674800A1 (en) 2000-01-27
NO20042393L (no) 2001-01-18
BG109682A (bg) 2007-03-30
HUP0103823A3 (en) 2003-05-28
PL348033A1 (en) 2002-05-06
WO2000004016A2 (en) 2000-01-27
CO5090830A1 (es) 2001-10-30
DK1418174T3 (da) 2009-05-18
NO20010298L (no) 2001-01-18
CZ307116B6 (cs) 2018-01-24
BG65150B1 (bg) 2007-04-30
SI1418174T1 (sl) 2009-08-31
CZ2001203A3 (en) 2001-05-16
JP2017061475A (ja) 2017-03-30
NZ509125A (en) 2003-02-28
EP2017269A8 (en) 2009-09-30
EP1097148B1 (en) 2004-03-17
HU0800267D0 (en) 2008-06-30
IL140492A (en) 2010-12-30
JP2014074047A (ja) 2014-04-24
SI2017269T1 (sl) 2012-02-29
CA2510949A1 (en) 2000-01-27
TWI362382B (en) 2012-04-21
DE69940616D1 (de) 2009-04-30
ES2372990T3 (es) 2012-01-30
PL194710B1 (pl) 2007-06-29
CN1310715A (zh) 2001-08-29
EP2298751A2 (en) 2011-03-23
SK922001A3 (en) 2001-07-10
EP1418174A2 (en) 2004-05-12
AR049658A2 (es) 2006-08-23
TR200100171T2 (tr) 2001-05-21
AR059763A2 (es) 2008-04-30
EP1418174A3 (en) 2004-06-23
IL191582A (en) 2016-02-29
CN1310715B (zh) 2010-11-03
JP4815050B2 (ja) 2011-11-16
CA2337846C (en) 2006-02-21
KR100793046B1 (ko) 2008-01-10
CY1112139T1 (el) 2015-11-04
HK1121155A1 (en) 2009-04-17
CZ2006533A3 (cs) 2001-05-16
IL187181A0 (en) 2008-02-09
PL213978B1 (pl) 2013-05-31
TW200716550A (en) 2007-05-01
KR20010072003A (ko) 2001-07-31
NZ522690A (en) 2004-04-30
JP5732212B2 (ja) 2015-06-10
IL140492A0 (en) 2002-02-10
EP2017269B1 (en) 2011-11-23
DE69915628D1 (en) 2004-04-22
BG65963B1 (bg) 2010-07-30
IL191582A0 (en) 2008-12-29
BR9912010A (pt) 2001-04-10
AR019431A1 (es) 2002-02-20
HUP0103823A2 (hu) 2002-02-28
ATE534636T1 (de) 2011-12-15
CA2510949C (en) 2009-11-17
ATE261947T1 (de) 2004-04-15
EP2017269A2 (en) 2009-01-21
AU5003799A (en) 2000-02-07
CN1502613A (zh) 2004-06-09
EP1418174B1 (en) 2009-03-18
CZ298188B6 (cs) 2007-07-18
ATE425974T1 (de) 2009-04-15
SI1097148T1 (en) 2004-10-31
CN101259128A (zh) 2008-09-10
KR100853371B1 (ko) 2008-08-22
MY145265A (en) 2012-01-13
HK1037918A1 (en) 2002-02-22
HU227540B1 (en) 2011-08-29
EP2298751A3 (en) 2011-08-17
ES2214038T3 (es) 2004-09-01
KR20060118022A (ko) 2006-11-17
PT1097148E (pt) 2004-05-31
CN101966180A (zh) 2011-02-09
NO318385B1 (no) 2005-03-14
PT1418174E (pt) 2009-06-08
SK287381B6 (sk) 2010-08-09
KR20040081137A (ko) 2004-09-20
TWI271400B (en) 2007-01-21
JP2002520410A (ja) 2002-07-09
DE69915628T2 (de) 2004-08-12

Similar Documents

Publication Publication Date Title
BG105197A (bg) Полиморфна форма на лекарствено средство
GEP20084461B (en) New derivative of 3,3- diphenyl-propylamine
IL143477A0 (en) A NEW PROCESS FOR THE PREPARATION OF 17-PHENYL-18,19,20-TRINOR-PGF2α AND ITS DERIVATIVES
BG103740A (bg) Фитостеролен състав за предпазване от болестта наалцхаймер
BG103882A (bg) Фармацевтични състави, съдържащи вориконазол
AU5242000A (en) Nematicidal trifluorobutenes
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
BG104179A (bg) Използване на фанхинон за лечението на болестта на алцхаймер
BG103649A (bg) Метод за получаване на епросартан
BG106002A (bg) Метод за получаване на пестицидни междинни съединения
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
BG106016A (bg) Производни на резорцинол
IL162188A0 (en) Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives
BG106151A (bg) Фармацевтичен комплекс
HUP0204430A3 (en) Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives, the obtained new compounds and pharmaceutical compositions containing thereof
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
AU7773700A (en) Method for the production or preparation of 2,6-dichlorotoluol
EP1335922A4 (en) NOVEL 4'-DEMETHYL-4'-O-SUBSTITUE-1-DEOXYPODOPHYLLOTOXIN DERIVATIVE, GEOMETRIC ISOMER THEREOF, PROCESS FOR PREPARING THE SAME, AND ANTI-CANCER COMPOSITION COMPRISING SAID DERIVATIVE
BG103986A (bg) Производни на пиролидинкарбоксилни киселини като ендотелинови антагонисти
IL137364A (en) Process for the preparation of 6,6-dimethylhept-1-en-4-yn-3-ol